Apologies appreciated. BTW - it is likely ZGNX board and poster drg369 that multi speaks of. I searched other boards for the lingo mentioned in this thread. If correct, I don't recognize the writing as any of the longs here. It is more like our shorts.... maybe works for the same hedge fund. Just paid to bash, but puts his own money in DNDN. That's my theory.
Hurricaine Sandy - Northeast sustained power outages resulted in poor storage conditions and wasted antigen per some sources (not confirmed, but believed by many on IV board to be the reason).
What is your evidence for sell? You just ask a question.... no answers.
The negatives work so hard against this stock. Can't they find a positive cause in the world to apply this passion?
Add - This is very old news. Desperate to bring it up now. Naked short are you or 'burned employee' still bent on fullest revenge?
Several in the know have hypothesized this antigen loss was due to hurricaine Sandy.
Great find! MarketEdge ratings have been very reliable IMO. This stock is finally a buy with a good power rating in the 80s and bullish signals throughout (except 200 day MA which takes time to curve back up). First time in months that MarketEdge doesn't have it listed as Avoid or Neutral. See also Stocktwits for several recent bullish charts posted by top gun traders.
Lacks medical background from bio on LinkedIn. Yes, like someone out of college 3 yrs really knows science / biotech potential! Works fully at SA per LinkedIn bio. I wonder if he were investigated if it would yield connections to short hedge funds? Does he really include all his potential financial disclosures relevant to DNDN? His articles are slanted to short side in an extreme, unbalanced manner.
Lehigh University? Credentials?
See Dendreon careers website. I guess they are going for the Hail Mary to reach breakeven by increasing sales and decreasing COGs as they stated on the DB call. I'm holding steady. Jan 3 2013 is when management / CEO received their last options (25% vest in 1 year). The GU ASCO is also in January in 2014. On the DB call, Greg Cox expected to provide a January update on Sales trends. There is potential for several positive surprises in Jan (Zytiga sequencing data, Neuvenge data, immune monitoring or EU study data). It may not be safe to be short over the holidays and early New Year.
They can't do that. It's an error. Try again. You probably already have a sell order posted for those shares. I just put a limit selll order on 70k shares for 50 and it worked fine.
That says it all!
oncology reps are being refocused on tumor biology across cancers vs specific products. May be a good fit for immunotheray / personalized medicines such as Provenge / Neuveneg for the Roche product line as a multi-tiered approach to cancer.